A Phase 1 Study to Assess the Effect of Moderate Renal Impairment on the Pharmacokinetics of CTP-543 (Deuruxolitinib Phosphate)
Latest Information Update: 01 Dec 2022
At a glance
- Drugs Deuruxolitinib (Primary)
- Indications Alopecia areata
- Focus Pharmacokinetics
- Sponsors Concert Pharmaceuticals
- 28 Nov 2022 Status changed from active, no longer recruiting to completed.
- 28 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2022 Planned End Date changed from 1 Sep 2022 to 1 Oct 2022.